ClinicalTrials.gg
RecruitingNCT06097845Updated Nov 19, 2026

Transcranial Ultrasound Via Sonolucent Cranioplasty

An interventional study of Transcranial Ultrasound in Cranioplasty, Sonolucent Cranioplasty and Reconstructive Cranioplasty, sponsored by Northwell Health. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Northwell Health · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.
Updated Nov 19, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Transcranial Ultrasound via Sonolucent Cranioplasty is a prospective, single arm, observational, open label (non-blinded) study to collect real world evidence on the use of transcranial ultrasound via sonolucent cranioplasty.

Read the detailed description

Standard of care (SOC) imaging techniques routinely used for neurosurgical monitoring, namely computed tomography (CT) and magnetic resonance imaging (MRI), present numerous patient, provider, and institutional burdens associated with transport, invasiveness, contrast administration, radiation exposure, imaging delay, and overall global costs. Ultrasound represents a promising alternative that overcomes many of these disadvantages being noninvasive, low-risk, real-time and portable, but is limited by the acoustic impedance of autologous cranial bone. Recently, material innovations enabling both transparent and sonolucent polymethyl methacrylate (PMMA) - a material commonly used for cranial reconstruction with a longstanding history of safety - have facilitated ultrasound windows within patients already receiving cranioplasty as standard of care. Early results applying transcranioplasty ultrasound (TCUS) through sonolucent cranial plates have been encouraging in regard to agreement with SOC imaging and advanced doppler capabilities. That said, limited published data exists commensurate with the novelty of the technique, therefore investigators herein aim to address this paucity by investigating the feasibility and efficacy of TCUS as compared to standard of care postoperative imaging modalities (i.e. MRI \& CT) in a prospective, quality control study.

02

Conditions studied

  • Cranioplasty
  • Sonolucent Cranioplasty
  • Reconstructive Cranioplasty

Keywords

  • Transcranial Ultrasound
  • SOC ultrasound
  • PMMA implant
03

In context

Lead sponsor

Northwell Health is the lead sponsor of 476 studies on the registry; 106 are open to participants now.

Of its 48 completed or terminated interventional studies of FDA-regulated products, 23 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated form.
  2. Stated willingness to comply with all study procedures and availability for the duration of the study.
  3. Patients who are undergoing reconstructive sonolucent cranioplasty as standard of care.
  4. Male or female, aged ≥ 18.

Exclusion criteria

Exclusion Criteria:

1. Patients who are pregnant

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Transcranial Ultrasound

    Ultrasound imaging will be performed by clinicians using FDA-approved ultrasound devices currently used in routine clinical practice.

    Diagnostic Test: Transcranial Ultrasound

Interventions

  • Diagnostic testTranscranial Ultrasound

    Patients who underwent reconstructive sonolucent cranioplasty will receive standard of care postoperative imaging (i.e. CT, MRI) in addition to ultrasound imaging. Ultrasound imaging will be performed by clinicians using FDA-approved ultrasound devices (GE Venue Go, Fujifilm Sonosite X-Porte, GE Volusion E10 and Clarius HD3 etc.) currently used in routine clinical practice.

06

What researchers measure

Primary outcomes

  1. Identification of Neuroanatomy accuracy of TCUS

    Accuracy metrics related to identification and measurement of neuroanatomy structures using Trasncranial Ultrasound

    Time frame: 12 months

  2. Diagnostic accuracy of TCUS

    Accuracy metrics related to detection of postoperative complications using Trasncranial Ultrasound

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Lenox Hill Hospital
    New York, New York 10075, United States
    Recruiting
    • Netanel Ben-Shalom, MD · Contactnbenshalom@northwell.edu · 212-434-3900
    • Tamika Wong, MPH · Contacttwong4@northwell.edu · 212-434-4836
    • Randy D'Amico, MD · Sub investigator
    • Heustein Sy, MD · Sub investigator
    • Vadim Zhigin, PA · Sub investigator
    • Olivia Albers, NP · Sub investigator
    • Tamika Wong, MPH · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2023 (actual). Primary completion is estimated for Dec 2028, 63 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Jun 2023 → Sep 2023, on Nov 19, 2026.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2027 → Dec 2028, on Sep 29, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2028 → Dec 2029, on Sep 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2023
First posted
Oct 24, 2023
StartActual
Sep 18, 2023was Jun 2023
Primary completionEst.
Dec 31, 2028was Dec 2027
CompletionEst.
Dec 31, 2029was Dec 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 27, 2023→Sep 18, 2023
Nov 19, 2026
Primary completion
Dec 31, 2027→Dec 31, 2028
Sep 29, 2026
Study completion
Dec 31, 2028→Dec 31, 2029
Sep 29, 2026
Show all 2 updates
  1. Nov 19, 2026
    Start date Jun 27, 2023→Sep 18, 2023
    + 1 other change: verification date
  2. Sep 29, 2026
    Primary completion Dec 31, 2027→Dec 31, 2028
    Study completion Dec 31, 2028→Dec 31, 2029
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06097845
Lead sponsor
Northwell Health
Responsible party
Netanel Ben-Shalom (Principal Investigator, Northwell Health) — Principal investigator
First posted
Oct 24, 2023
Start date
Sep 18, 2023
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

Netanel Ben-Shalom, MD
Contact
nbenshalom@northwell.edu
212-434-3900
Tamika Wong, MPH
Contact
twong4@northwell.edu
212-434-4836
Netanel Ben-Shalom, MD
principal investigator · Lenox Hill Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion